Ingevity, Corp. (NGVT)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
$70.54+1.02%
Close 2026-09-04 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
QuarterlyIQ Insights · NGVT
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $71 NGVT trades at 15× p/e, below its 17× p/e peer median, but our blended $60 fair value sits below the price. It's a high-confidence read. Even valued only for durable growth at sustainable margins, it's worth about $75 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| dcf fcfe | 12M | $12.43 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $121.66 | — | — | Hist. CAGR | high |
| graham number | 12M | $12.02 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $119.90 | 10.0 | 15.13 | TTM | high |
| Peer P/FCF | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $92.56 |
| 21.1 |
| 4.39 |
| TTM |
| high |
| Peer P/E | 12M | $83.83 | 17.4 | 4.83 | TTM | high |
| Peer P/S | 12M | $47.65 | 1.4 | 32.89 | TTM | high |
| residual income | 12M | $19.11 | — | — | TTM | high |
| Own P/E history | 12M | $71.13 | 14.7 | 4.83 | TTM | high |
| triangulated | 12M | $93.63 | 17.4 | 5.39 | Triangulated | high |
| Peer P/FCF | 3Y | $119.88 | 21.1 | 5.69 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $95.59 | 17.4 | 5.51 | Hist. CAGR(prov.) | medium |
| Peer P/S | 3Y | $40.60 | 1.4 | 28.02 | guidance | medium |
| Own P/E history | 3Y | $81.10 | 14.7 | 5.51 | Hist. CAGR(prov.) | medium |
| Peer P/FCF | 5Y | $142.44 | 21.1 | 6.76 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $85.91 | 17.4 | 4.95 | Hist. CAGR(prov.) | high |
| Peer P/S | 5Y | $36.49 | 1.4 | 25.19 | guidance | high |
| Own P/E history | 5Y | $72.89 | 14.7 | 4.95 | Hist. CAGR(prov.) | high |